NCT05740943 2026-01-20
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT04621188 2025-09-24
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT06410040 2024-05-10
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
Sichuan Cancer Hospital and Research Institute
Active not recruiting